Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Verisante Technology Inc. (VRSEF : OTC)

• Company Description    Verisante Technology, Inc. operates as a medical device company engaged in the development of innovative systems for the early detection of cancer. It develops and offers a range of compact, non?invasive cancer detection devices for many of the most common cancers, including gastro?intestinal, colorectal and cervical cancers. The Company's Verisante Aura series is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. Other product offered by the company includes Verisante Core series and Authenticare- a pre-production prototype of a pharmaceutical tablet analyzer for the authentication of solid dosage pharmaceuticals. Verisante Technology, Inc. is based in Vancouver, British Columbia. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 50 shares Shares Outstanding: 43.94 (millions) Market Capitalization: $0.10 (millions) Beta: 17.73 52 Week High: $0.01 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.55% 0.63% 12 Week -60.35% -66.64% Year To Date -54.00% -56.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 170-422 Richards Street - Vancouver,A1 V6B 2Z4 CAN ph: 604-716-5133 fax: 604-605-0508 None http://www.verisante.com

• General Corporate Information    Officers Thomas Braun - Chief Executive Officer and Director Emmeline Braun - Chief Financial Officer and Director Jake Thiessen - Director Vincent Trinh - Director Jake J. Thiessen - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 92346G203 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/28/25 Share - Related Items Shares Outstanding: 43.94 Most Recent Split Date: 6.00 (0.10:1) Beta: 17.73 Market Capitalization: $0.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/28/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -901.36 12/31/24 - -610.70 Current Ratio 06/30/25 - - 03/31/25 - 0.53 12/31/24 - 0.70 Quick Ratio 06/30/25 - - 03/31/25 - 0.53 12/31/24 - 0.70 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©